<DOC>
	<DOCNO>NCT01222117</DOCNO>
	<brief_summary>The primary purpose Phase 2 study optimize Plasmin delivery compare different delivery regimens patient peripheral arterial occlusion . The study include blind plasminogen activator treatment group blind plasminogen activator placebo group . The study also assess safety tolerability Plasmin 150 250 mg dos .</brief_summary>
	<brief_title>A Study Intra-thrombus Plasmin ( Human ) In Acute Peripheral Arterial Occlusion</brief_title>
	<detailed_description />
	<mesh_term>Arterial Occlusive Diseases</mesh_term>
	<mesh_term>Plasminogen</mesh_term>
	<mesh_term>Fibrinolysin</mesh_term>
	<mesh_term>Tissue Plasminogen Activator</mesh_term>
	<criteria>Unilateral limb ischemia Society Vascular Surgery Categories I IIa Onset symptom less equal 14 day Thrombosed infrainguinal bypass graft native artery Diagnosis arteriography occlusive thrombus graft artery Ability embed infusion catheter thrombus Women childbearing potential must use contraception negative pregnancy test Any medical social condition may interfere study participation Women pregnant lactate Hemorrhagic stroke history Thrombotic embolic stroke cerebrovascular event ( include transient ischemic attack ) within one year Intracranial spinal neurosurgery , severe intracranial trauma last 3 month Major surgery , organ biopsy , major trauma within past 10 day Lumbar puncture noncompressible arterial puncture past 10 day Intraocular surgery within past 10 day Active gastrointestinal organ bleed Uncontrolled arterial hypertension ( systolic blood pressure &gt; 180 mmHg diastolic blood pressure &gt; 110 mmHg ) Known intracranial neoplasm , aneurysm , arteriovenous malformation Current bleeding diathesis Platelet count &lt; 75 x 10e9/L Active graft infection Occlusion occur within one month synthetic graft placement Occlusion occur within 6 month autologous graft placement A sequential composite graft dual outflow correct multiple occlusion Medically unable tolerate open vascular procedure Known prothrombotic state Hemoglobin &lt; 10.0 g/dL Impaired renal function renal disease constitute contraindication contrast angiography , include creatinine &gt; 2.0 mg/dL Treatment full dose plasminogen activator ( PA ) within last 48 hour Treatment glycoprotein IIb/IIIa class platelet inhibitor within past 5 day Treatment oral anticoagulant , international normalize ratio &gt; 1.7</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>Acute Limb Ischemia</keyword>
</DOC>